Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.19 USD
−54.05 M USD
4.05 M USD
286.77 M
About Ocugen, Inc.
Sector
Industry
CEO
Shankar Musunuri
Website
Headquarters
Malvern
Founded
2013
FIGI
BBG00194VJB1
Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.
Related stocks
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on BOATS exchange Ocugen, Inc. stocks are traded under the ticker OCGN.
We've gathered analysts' opinions on Ocugen, Inc. future price: according to them, OCGN price has a max estimate of 8.00 USD and a min estimate of 4.00 USD. Watch OCGN chart and read a more detailed Ocugen, Inc. stock forecast: see what analysts think of Ocugen, Inc. and suggest that you do with its stocks.
Yes, you can track Ocugen, Inc. financials in yearly and quarterly reports right on TradingView.
Ocugen, Inc. is going to release the next earnings report on Aug 1, 2025. Keep track of upcoming events with our Earnings Calendar.
OCGN earnings for the last quarter are −0.05 USD per share, whereas the estimation was −0.06 USD resulting in a 13.04% surprise. The estimated earnings for the next quarter are −0.06 USD per share. See more details about Ocugen, Inc. earnings.
Ocugen, Inc. revenue for the last quarter amounts to 1.48 M USD, despite the estimated figure of 0.00 USD. In the next quarter, revenue is expected to reach 466.67 K USD.
OCGN net income for the last quarter is −15.35 M USD, while the quarter before that showed −13.88 M USD of net income which accounts for −10.59% change. Track more Ocugen, Inc. financial stats to get the full picture.
No, OCGN doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jul 27, 2025, the company has 95 employees. See our rating of the largest employees — is Ocugen, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Ocugen, Inc. EBITDA is −54.34 M USD, and current EBITDA margin is −1.30 K%. See more stats in Ocugen, Inc. financial statements.
Like other stocks, OCGN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Ocugen, Inc. stock right from TradingView charts — choose your broker and connect to your account.